HPV-based Screening Among Women 23-29 Years of Age

Condition(s) studied

Investigational drug(s) / intervention(s)

HPV testing: All women age 23-29 resident in the pilot counties will be invited to HPV screening as of the study start date. The same invitation as currently used for women aged 30 and upwards will be used. This information clearly states that it is possible to opt out of the program and that data from the screening program will be collected to regional and national quality registers who will systematically evaluate the quality of the care. At the screening station, the samples are collected identically regardless of primary screening test used - there is no change in the procedures used neither for the woman or for the midwives taking the sample. HPV testing will be performed using the same purchased, CE-marked and accredited HPV screening platforms as currently used for women aged 30 and upwards. The cytology is according to the liquid-based cytology method.

Study summary

The aim of the trial is to determine whether organized screening with primary HPV analysis provide higher cancer protection in the age group 23-29 years compared to primary cytology.

Eligibility

Primary outcome measure(s)

• Incidence of cervical cancer — Measured once during 1 year, year 1.
  Cervical cancer incidence in the intervention group compared to a historical control group.
• Incidence of cervical cancer — Measured once during 1 year, year 2.
  Cervical cancer incidence in the intervention group compared to a historical control group.
• Incidence of cervical cancer — Measured once during 1 year, year 3.
  Cervical cancer incidence in the intervention group compared to a historical control group.
• Incidence of cervical cancer — Measured once during 1 year, year 4.
  Cervical cancer incidence in the intervention group compared to a historical control group.
• Incidence of cervical cancer — Measured once during 1 year, year 5.
  Cervical cancer incidence in the intervention group compared to a historical control group.
• Incidence of cervical cancer — Measured once during 1 year, year 6.
  Cervical cancer incidence in the intervention group compared to a historical control group.
• Incidence of cervical cancer — Measured once during 1 year, year 7.
  Cervical cancer incidence in the intervention group compared to a historical control group.
• Incidence of cervical cancer — Measured once during 1 year, year 8.
  Cervical cancer incidence in the intervention group compared to a historical control group.
• Incidence of cervical cancer — Measured once during 1 year, year 9.
  Cervical cancer incidence in the intervention group compared to a historical control group.
• Incidence of cervical cancer — Measured once during 1 year, year 10.
  Cervical cancer incidence in the intervention group compared to a historical control group.

Trial sites (2)

More Karolinska Institutet trials in Sweden

Other trials for the same condition